Clinsight
Clinsight provides an AI-powered precision pathology platform for prostate cancer analysis. Its ClinAI™ Prostate system autonomously analyzes standard biopsy slides, detecting cancer with 96% sensitivity and ruling out 97% of healthy cases in under five minutes per case. The platform performs automated Gleason grading and predicts biochemical recurrence with over 90% accuracy, built on a dataset of 15,000 patients and 280,000 slides.
- Healthcare Technology
- Artificial Intelligence
- Digital Health
- Data & Analytics
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Prostate cancer diagnosis and risk assessment traditionally rely on manual pathology review, which is time-consuming, subject to inter-observer variability, and can delay treatment decisions. The growing volume of biopsy cases strains pathology workflows, and standard methods often lack precise, outcome-based risk stratification to guide clinical and pharmaceutical decisions.
Solution
ClinAI provides an AI-powered precision pathology platform for prostate cancer. Its ClinAI™ Prostate system autonomously analyzes standard biopsy slides, detecting cancer with 96% sensitivity and ruling out 97% of healthy cases in under five minutes per case. The platform performs automated Gleason grading, detects perineural invasion and cribriform morphologies, and predicts patient outcomes such as biochemical recurrence with over 90% accuracy. Built on a dataset of 15,000 patients and 280,000 slides with 15 years of follow-up, the system is offered as a Research Use Only (RUO) solution for pathology laboratories and pharmaceutical companies.
Target Audience
Primary customers are private pathology laboratories seeking increased throughput and diagnostic consistency, and pharmaceutical companies needing precise patient stratification for clinical trials based on risk and predicted outcome.
Features
- Autonomous analysis of standard biopsy slides with 96% cancer detection sensitivity and 97% healthy case exclusion
- Sub-five-minute analysis time per case for high-throughput workflows
- Automated Gleason grading, cancer extent measurement, and detection of perineural invasion and cribriform morphologies
- Outcome-based risk prediction of biochemical recurrence (BCR) with over 90% accuracy
- Trained on a dataset of 15,000 patients and 280,000 slides with 15 years of clinical follow-up
- Research Use Only (RUO) configuration designed for laboratory and pharmaceutical applications